NeoRx responds to FDA:
This article was originally published in Clinica
Executive Summary
NeoRx has submitted to the US FDA data from a phase II dosimetry study of its Skeletal Targeted Radiotherapy (STR) technique in patients with multiple myeloma, a cancer of the bone marrow. The dosimetry study was requested by the FDA to validate the patient-specific dosing method the company had used in earlier studies. NeoRx has also submitted to the agency a revised proposal for further clinical development of STR. "We believe that STR offers distinct advantages for transplant-eligible patients with multiple myeloma, a cancer that currently has no cure," says Douglass Given, president and CEO of the Seattle, Washington firm.